Literature DB >> 7115016

Increased brain dopamine and dopamine receptors in schizophrenia.

A V Mackay, L L Iversen, M Rossor, E Spokes, E Bird, A Arregui, I Creese, S H Synder.   

Abstract

In postmortem samples of caudate nucleus and nucleus accumbens from 48 schizophrenic patients, there were significant increases in both the maximum number of binding sites (Bmax) and the apparent dissociation constant (KD) for tritiated spiperone. The increase in apparent KD probably reflects the presence of residual neuroleptic drugs, but changes in Bmax for tritiated spiperone reflect genuine changes in receptor numbers. The increases in receptors were seen only in patients in whom neuroleptic medication had been maintained until the time of death, indicating that they may be entirely iatrogenic. Dopamine measurements for a larger series of schizophrenic and control cases (n greater than 60) show significantly increased concentrations in both the nucleus accumbens and caudate nucleus. The changes in dopamine were not obviously related to neuroleptic medication and, unlike the receptor changes, were most severe in younger patients.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7115016     DOI: 10.1001/archpsyc.1982.04290090001001

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  57 in total

Review 1.  Biomarkers for the effects of antipsychotic drugs in healthy volunteers.

Authors:  S J de Visser; J van der Post; M S Pieters; A F Cohen; J M van Gerven
Journal:  Br J Clin Pharmacol       Date:  2001-02       Impact factor: 4.335

2.  Dopamine receptors mediate strategy abandoning via modulation of a specific prelimbic cortex-nucleus accumbens pathway in mice.

Authors:  Qiaoling Cui; Qian Li; Hongyan Geng; Lei Chen; Nancy Y Ip; Ya Ke; Wing-Ho Yung
Journal:  Proc Natl Acad Sci U S A       Date:  2018-05-07       Impact factor: 11.205

3.  G-proteins (Gi, Go) in the basal ganglia of control and schizophrenic brain.

Authors:  F Okada; T J Crow; G W Roberts
Journal:  J Neural Transm Gen Sect       Date:  1990

Review 4.  Agonist high- and low-affinity states of dopamine D₂ receptors: methods of detection and clinical implications.

Authors:  Jan-Peter van Wieringen; Jan Booij; Vladimir Shalgunov; Philip Elsinga; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-12-09       Impact factor: 3.000

5.  Schizophrenia Exhibits Bi-directional Brain-Wide Alterations in Cortico-Striato-Cerebellar Circuits.

Authors:  Jie Lisa Ji; Caroline Diehl; Charles Schleifer; Carol A Tamminga; Matcheri S Keshavan; John A Sweeney; Brett A Clementz; S Kristian Hill; Godfrey Pearlson; Genevieve Yang; Gina Creatura; John H Krystal; Grega Repovs; John Murray; Anderson Winkler; Alan Anticevic
Journal:  Cereb Cortex       Date:  2019-12-17       Impact factor: 5.357

6.  Uncovering the role of the nucleus accumbens in schizophrenia: A postmortem analysis of tyrosine hydroxylase and vesicular glutamate transporters.

Authors:  Lesley A McCollum; Rosalinda C Roberts
Journal:  Schizophr Res       Date:  2015-09-18       Impact factor: 4.939

7.  Neurochemical heterogeneity of the primate nucleus accumbens.

Authors:  K Ikemoto; K Satoh; T Maeda; H C Fibiger
Journal:  Exp Brain Res       Date:  1995       Impact factor: 1.972

8.  Behavioral and neurobiological changes in C57BL/6 mouse exposed to cuprizone: effects of antipsychotics.

Authors:  Haiyun Xu; Hong-Ju Yang; Bryan McConomy; Ronald Browning; Xin-Min Li
Journal:  Front Behav Neurosci       Date:  2010-03-18       Impact factor: 3.558

Review 9.  Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction.

Authors:  Patricia S Goldman-Rakic; Stacy A Castner; Torgny H Svensson; Larry J Siever; Graham V Williams
Journal:  Psychopharmacology (Berl)       Date:  2004-04-30       Impact factor: 4.530

10.  Studies in postmortem dopamine uptake. II. Alterations of the synaptosomal catecholamine uptake in postmortem brain regions in schizophrenia.

Authors:  N Haberland; L Hetey
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.